Table 7.
Soft Tissue Sarcoma.
| Reference | Type of study | Site | n | Treatment | Tumor response | Survival | HT-associated adverse events |
|---|---|---|---|---|---|---|---|
| Issels et al62 | Randomized phase 3 multicentric study | Soft tissue sarcoma | 329 | Neoadjuvant 162 CHT-HT 167 CHT |
Response rate CHT-HT =3 8% CHT = 29% |
CHT-HT group: OS median = 15.4 years (P = .04), 5-year OS = 62.7%, 10-year OS = 51.3% CHT group: OS median = 6.2 years, 5-year OS = 52.6%, 10-year OS = 42.7% |
HT-related adverse events were G1 and G2: pain, bolus pressure, and skin burn |
| Fendler et al60 | Retrospective observational | Soft tissue sarcoma | 66 | Neoadjuvant CHT-HT |
Response rate = 60% | OS median = 22.2 months | |
| Angele et al61 | Randomized phase-III multicenter study | Soft tissue sarcoma | 149 | 73 CHT-HT 66 CHT |
Soft tissue sarcoma CHT-HT = 34.7% vs CHT = 15.6% | CHT-HT group: 5-year OS = 57%, DFS = 34% (P = .04), and LRFS = 56% (P = .044) CHT group: 5-year OS = 55%, DFS = 27%, and LRFS = 45% |
|
| Schlemmer et al63 | Phase II, nonrandomized | High-risk soft tissue sarcoma | 47 | Neoadjuvant HT + surgery + CHT + RT | Soft tissue sarcoma = 21% | Median OS = 105 months 5-year OS = 57%, DFS = 55%, and LRFS = 48% |
Abbreviations: HT, hyperthermia; CHT, chemotherapy; OS, overall survival; G, grade; DFS, disease-free survival; LRFS, local relapse-free survival.